2. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
3. Webb DI, Ubogy G, Silver RT. Importance of bone marrow biopsy in the clinical staging of Hodgkin’s disease. Cancer 1970;26:313–317.
4. Painter D, Smith A, de Tute R, Crouch S, Roman E, Jack A. The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients. Br J Haematol 2015;170:175–178.
5. Anderson J, Armitage JO, Berger F, et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma: a report of the Non-Hodgkin’s lymphoma classification project. Blood 1997;88:3909–3918.
6. Moid F, DePalma L. Comparison of relative value of bone marrow aspirates and bone marrow trephine biopsies in the diagnosis of solid tumor metastasis and Hodgkin lymphoma: institutional experience and literature review. Arch Pathol Lab Med 2005;129:497–501.
8. Aljadayeh MH, Saidat SD, Kamal N, et al. Comparative evaluation between bone marrow aspirate and biopsy morphologic findings: experience at King Hussein Medical Center. JRMS 2015;22:18–22.
9. NCCN B-cell lymphoma panel members, D. ZA, Gordon LI, et alNCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) : B-cell lymphomas, version I.2017. Washington: National Comprehensive Cancer Network, 2016.
10. NCCN T-Cell lymphomas panel members, D. ZA, Gordon LI, et alNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) : T-cell lymphomas, version I.2017. Washington: National Comprehensive Cancer Network, 2016.
11. Guerard EJ, Bishop MR. Overview of non-Hodgkin’s lymphoma. Dis Mon 2012;58:208–218.
12. Arima H, Maruoka H, Nasu K, et al. Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. Leuk Lymphoma 2013;54:2645–2653.
13. Dick F, Bloomfield CD, Brunning RD. Incidence cytology, and histopathology of non-Hodgkin’s lymphomas in the bone marrow. Cancer 1974;33:1382–1398.
15. Liao KT. The superiority of histologic sections of aspirated bone marrow in malignant lymphomas. A review of 1,124 examinations. Cancer 1971;27:618–628.
16. Grann V, Pool JL, Mayer K. Comparative study of bone marrow aspiration and biopsy in patients with neoplastic disease. Cancer 1966;19:1898–1900.
17. Pettet JD, Pease GL, Cooper T. An evaluation of paraffin sections of aspirated bone marrow in malignant lymphomas. Blood 1955;10:820–830.
18. Hantaweepant C, Chinthammitr Y, Khuhapinant A, Sukpanichnant S. Clinical significance of bone marrow involvement as confirmed by bone marrow aspiration vs. bone marrow biopsy in diffuse large B-cell lymphoma. J Med Assoc Thai 2016;99:262–269.
19. Mahdi AJ, Elmusharaf N, Osman H, Thompson I. Atypical blood and bone marrow lymphocytes in ALK-positive anaplastic T-cell lymphoma: important lessons. BMJ Case Rep 2013;2013.
20. Li YP, Zhang ZH, Zhao FT. Value of multiparameter flow cytometry in diagnosis of non-Hodgkin’s lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2016;24:102–105.
21. Crotty PL, Smith BR, Tallini G. Morphologic, immunophenotypic, and molecular evaluation of bone marrow involvement in non-Hodgkin’s lymphoma. Diagn Mol Pathol 1998;7:90–95.